Microbix Biosystems Inc
TSX:MBX
Intrinsic Value
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. [ Read More ]
The intrinsic value of one
MBX
stock under the Base Case scenario is
0.63
CAD.
Compared to the current market price of 0.335 CAD,
Microbix Biosystems Inc
is
Undervalued by 47%.
Microbix Biosystems Inc's market capitalization is 45.7m CAD.
MBX stock price is 0.335 CAD.
MBX stock price (0.335 CAD) is 47% less than its Intrinsic Value (0.63 CAD).
MBX stock price (0.335 CAD) is 49% less than its Relative Value (0.652 CAD). Open Relative Valuation
MBX has upside potential of 144% compared to the average analyst price target.
Open Wall St Estimates
MBX has positive Free Cash Flow for the last twelve months.
MBX's ROE (Return on Equity) for the past 12 months is positive and is equal to 15%.
MBX has positive three-year average ROIC (Return on Invested Capital): 8%. The company is efficient at using invested capital to generate operating income.
MBX has positive Operating Income for the last twelve months.
MBX's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 20%.
MBX's Revenue has grown by an exceptional 34% over the past 12 months.
MBX has positive Net Income for the last twelve months.
MBX's ROE (Return on Equity) has significantly increased in the last 3 years from -44% to 15%.
MBX's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -11% to 20%.
MBX's Revenue has been growing by an exceptional 24% per year for the last 3 years.
MBX's Revenue is forecast to grow at a rate of 34% per year over the next 3 years.
MBX has negative three-year average ROE (Return on Equity): -2%. The company is not efficient at transforming stockholders' equity into net income.
MBX has negative Net Debt. This means that the company has more cash and short-term investments (13m CAD) than debt (6m CAD).
MBX's Altman Z-Score is very high and is equal to 3.3.
MBX has positive Gross Profit for the last twelve months.
MBX's D/E (Debt to Equity) is very low and is equal to 0.24.
MBX's long-term assets (37m CAD) exceed its long-term liabilties (9m CAD).
MBX's short-term assets (24m CAD) exceed its short-term liabilties (3m CAD).
Valuation Backtest
Microbix Biosystems Inc
Run backtest to discover the historical profit from buying and selling
MBX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Microbix Biosystems Inc
Balance Sheet Decomposition
Microbix Biosystems Inc
| Current Assets | 23.7m |
| Cash & Short-Term Investments | 12.8m |
| Receivables | 3.9m |
| Other Current Assets | 7.1m |
| Non-Current Assets | 13m |
| PP&E | 8.7m |
| Intangibles | 4.3m |
| Current Liabilities | 2.8m |
| Accounts Payable | 1.8m |
| Other Current Liabilities | 989.2k |
| Non-Current Liabilities | 6.7m |
| Long-Term Debt | 6.4m |
| Other Non-Current Liabilities | 291.8k |
Earnings Waterfall
Microbix Biosystems Inc
|
Revenue
|
22.4m
CAD
|
|
Cost of Revenue
|
-9.9m
CAD
|
|
Gross Profit
|
12.5m
CAD
|
|
Operating Expenses
|
-8.4m
CAD
|
|
Operating Income
|
4.1m
CAD
|
|
Other Expenses
|
-394.5k
CAD
|
|
Net Income
|
3.7m
CAD
|
Free Cash Flow Analysis
Microbix Biosystems Inc
MBX Profitability Score
Profitability Due Diligence
Microbix Biosystems Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Microbix Biosystems Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
MBX Solvency Score
Solvency Due Diligence
Microbix Biosystems Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Microbix Biosystems Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MBX Price Targets Summary
Microbix Biosystems Inc
According to Wall Street analysts, the average 1-year price target for
MBX
is 0.816 CAD
with a low forecast of 0.808 CAD and a high forecast of 0.84 CAD.
Shareholder Return
MBX Price
Microbix Biosystems Inc
| Average Annual Return | 25.12% |
| Standard Deviation of Annual Returns | 67.1% |
| Max Drawdown | -72% |
| Market Capitalization | 45.7m CAD |
| Shares Outstanding | 136 550 373 |
| Percentage of Shares Shorted | 0.25% |
Company Profile
Microbix Biosystems Inc
Country
Industry
Market Cap
Dividend Yield
Description
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm manufactures a range of biological materials for the diagnostics industry, notably antigens (Antigen business) used in immunoassays and its quality assessment and proficiency testing controls (QAPs business). The firm operates in two segments: the development, manufacturing, and sales of antigens as materials for the medical diagnostic industry or as quality assessment products (as finished products) and viral transport medium (VTM) and the development and commercialization of products or technologies such as Kinlytic and . The Kinlyti urokinase, which is a biologic thrombolytic drug used to treat blood clots. The firm's catalogue of catalogue covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually transmitted and insect-borne diseases. Its QAPs are available in over 30 countries.
Contact
IPO
Employees
Officers
The intrinsic value of one
MBX
stock under the Base Case scenario is
0.63
CAD.
Compared to the current market price of 0.335 CAD,
Microbix Biosystems Inc
is
Undervalued by 47%.
You don't have any saved screeners yet
